v3.25.4
Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets:      
Net operating loss carryforwards $ 108,888 $ 102,145  
Tax credit carryforwards 10,926 10,931  
Accrued expenses 210 132  
Property and equipment 0 28  
Lease liabilities 0 0  
Equity compensation 1,089 2,191  
Amortizable intangibles 867 984  
Amortizable research expenditures [1] 12,236 17,958  
Other 64 64  
Gross deferred tax assets 134,280 134,433  
Deferred tax liabilities:      
Right of use assets 0 0  
Gross deferred tax liabilities 0 0  
Valuation allowance (134,280) (134,433) $ (125,055)
Net deferred tax assets $ 0 $ 0  
[1] Under the Tax Cuts and Jobs Act (TCJA), research and experimental (R&D) expenditures are capitalized and amortized under section 174 for tax years beginning after December 31, 2021. These costs are amortized for tax purposes over 5 years since the R&D was performed in the U.S. The One Big Beautiful Bill Act (OBBBA) was enacted on July 4, 2025. OBBBA includes modifications to several provisions of TCJA, including reinstating full expensing for domestic R&D expenditures. The Company is considering the OBBBA amendments and transition rules for domestic R&D expenditures that were previously capitalized under TCJA. The unamortized balance of these costs is presented as a deferred tax asset in the table above.